Ornidazole

P01A - Agents against amoebiasis and other protozoal diseases ATC P01AB03 Small molecule Natural product

JFDA label: Tiberal-AD

Mechanism of Action

— Produces reactive intermediates

Indications

Approved

Amebiasis — amebiasis
Bacterial Infections — bacterial disease

Off-label

Colonic Neoplasms
Rectal Neoplasms

Pregnancy & Lactation

Pregnancy

Lactation

Caution Hale L3

Ornidazole is not approved for marketing in the United States by the U.S.

Chemistry & Properties

Formula	C7H10ClN3O3
Molecular weight	219.63 g/mol
IUPAC name	1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
CAS	16773-42-5
PubChem CID	28061
InChIKey	`IPWKIXLWTCNBKN-UHFFFAOYSA-N`
logP	0.7 (XLogP 0.6)
Polar surface area	81.19 Å²
H-bond acceptors / donors	5 / 1
Drug-likeness (QED)	0.46
Lipinski violations	0

SMILES

Cc1ncc([N+](=O)[O-])n1CC(O)CCl

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrant	Yes

Enzyme interactions

Enzyme	Role	Detail
CYP2C19	Substrate	—
CYP2C9	Substrate	—
CYP3A4	Substrate	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (3)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Biteral	Tablet 500 mg	10 tab	Hikma Pharmaceuticals Co.Ltd/Jordan	5.000
Tibirex	Tablet 500 mg	10 tab	Hayat Pharmaceutical Industries CO.PLC/JORDAN	5.000
Tiberal-AD	Tablet 500 mg	10 tab	The Arab Pharmaceutical Manufactruing Co.	5.310